Skip to content

Continuing 3TC therapy after viral rebound shows no benefit

Nevirapine hepatotoxicity after treatment switch no more likely at higher CD4 counts

Resistance testing may be useful for some with 'undetectable' viral loads

One-in-six interrupt treatment within two years of initiating ART

Draft BHIVA treatment guidelines: respond by Monday September 4th

Kaletra monotherapy as effective as triple therapy for at least 18 months

Kaletra monotherapy - more encouraging results

Darunavir/ritonavir superior virologically and immunologically to comparator drugs over one year

NRTI-sparing combination of ritonavir-boosted indinavir and efavirenz improves fat loss but worsens blood fat and sugar levels